Rigel Pharma: Formulating A Game Plan For 2026

2026-01-01 04:41:46 ET

It has been seven years since my first Rigel Pharmaceuticals ( RIGL ) article, where I was bullish on TAVALISSE and the company's impressive pipeline. I was eyeing a potential buy early in 2019 as the company continued to make headway clinically and commercially. Eventually, I established a position in RIGL, and have covered the ticker over a dozen times since my first article. Obviously, the company has changed over the past seven years, as Rigel brought in GAVRETO and REZLIDHIA to help bolster their commercial portfolio. Rigel is starting to benefit with Q3 2025 revenue of $69.5M, net income of $27.9M, and cash and investments of $137.1M. In addition, the company is raising their full-year 2025 revenue guidance to $285M-$290M and is projecting 55%-59% year-over-year commercial growth, while still funding both existing and new pipeline efforts. However, despite my long-standing bullish outlook for Rigel, I'm going to keep an eye on Rigel's earnings throughout 2026 to see if they can maintain the momentum they have established over the past couple of years....

Read the full article on Seeking Alpha

For further details see: